1257050-69-3

Upstream product

• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 1489-97-0 ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 
• 98-59-9 p-toluenesulfonyl chloride 
• 57899-62-4 triethyl 4-oxocyclohexane-1,1,3-tricarboxylate 
• 92454-00-7 pentane-1,3,3,5-tetracarboxylic acid-3,3-diethyl ester 
• 1256546-71-0 8,8-diethyl 1,4-dioxaspiro[4.5]decane-8,8-dicarboxylate 
• 55704-60-4 4-oxo-cyclohexane-1,1-dicarboxylic acid diethyl ester 
• 1256546-72-1 [8-(hydroxymethyl)-1,4-dioxaspiro[4.5]decan-8-yl]methanol 

Downstream Products

• 340022-81-3 (4-oxocyclohexane-1,1-diyl)bis(methylene) bis(4-methylbenzenesulfonate) 
• 1380665-32-6 N-[7-(chloromethyl)-2-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-carbamic acid phenylmethyl ester 
• 1380665-41-7 N'-[2-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-6,7,8,9-tetrahydro-7-(hydroxymethyl)-4-oxo-3-(phenylmethoxy)-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-N,N-dimethyl-ethanediamide 
• 1380662-06-5 N'-[2-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-6,7,8,9-tetrahydro-3-hydroxy-7-(hydroxymethyl)-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-N,N-dimethyl-ethanediamide 
• 1380665-45-1 N₂-[2-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-7-formyl-6,7,8,9-tetrahydro-4-oxo-3-(phenylmethoxy)-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-N₁,N₁-dimethyl-ethanediamide 
• 1380665-42-8 N₂-[2-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-6,7,8,9-tetrahydro-4-oxo-3-(phenylmethoxy)-7-[[(tetrahydro-2H-pyran-4-yl)amino]methyl]-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-N₁,N₁-dimethyl-ethanediamide 
• 1380662-05-4 N'-[2-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-6,7,8,9-tetrahydro-3-hydroxy-7-[[[(4-methylphenyl)sulfonyl]oxy]methyl]-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-N,N-dimethyl-ethanediamide 
• 1380662-19-0 N-[2-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-6,7,8,9-tetrahydro-3-hydroxy-7-(hydroxymethyl)-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-n,N',N'-trimethyl-ethanediamide 
• 1380662-28-1 N-[7-(cyanomethyl)-2-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-n,N',N'-trimethyl-ethanediamide 
• 1380662-29-2 N-[7-(fluoromethyl)-2-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-N,N',N'-trimethyl-ethanediamide 
• 1380662-30-5 N-[2-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-6,7,8,9-tetrahydro-3-hydroxy-7-(methoxymethyl)-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-N,N',N'-trimethyl-ethanediamide 
• 1380662-31-6 N-[7-(cyanomethyl)-2-[[[(4-fluorophenyl)methyl]amino]carbonyl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-n,N',N'-trimethyl-ethanediamide 
• 1380662-35-0 N-[7-(fluoromethyl)-2-[[[(4-fluorophenyl)methyl]amino]carbonyl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-n,N',N'-trimethyl-ethanediamide 
• 1380662-90-7 N'-[7-(chloromethyl)-2-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-N,N-dimethyl-ethanediamide 

Relevant academic research and scientific papers

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad spectrum antibacterial agents

Bacterial resistance is eroding the clinical utility of existing antibiotics necessitating the discovery of new agents. Bacterial type II topoisomerase is a clinically validated, highly effective, and proven drug target. This target is amenable to inhibit

BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS

Novel bridged bicyclic compounds are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antibacterial agents. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating bacterial infections and associated diseases and conditions.

HIV INTEGRASE INHIBITORS

The disclosure generally relates to the novel compounds of formula (I), including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invent